Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E Wee

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 11, 2023
Management of testicular germ cell tumorsChristopher E Wee, Timothy D Gilligan
Southern Medical Journal|February 5, 2020
Changes in Health and Well-Being during Residents' TrainingChristopher E Wee, Jacob Petrosky, Lauren Mientkiewicz, et al.
The Prostate|July 13, 2021
Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experienceChristopher E Wee, Brian A Costello, Jacob J Orme, et al.
Frontiers in Endocrinology|July 17, 2023
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionJarrell Imamura, Shinjini Ganguly, Andrew Muskara, et al.
Journal of Oncology Practice|June 22, 2017
Analysis of Origins of Admission for Solid Tumor Oncology Inpatients: Disease Severity and OutcomesChristopher E Wee, Lindsey M Goodman, Leticia Varella, et al.
Clinical Genitourinary Cancer|January 20, 2024
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse EventsAmanda Nizam, Ryan K Rader, Alice Tzeng, et al.
Clinical Genitourinary Cancer|November 6, 2023
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell CarcinomaJames Schuster, Iris Y Sheng, Chandana A Reddy, et al.
Clinical Genitourinary Cancer|August 29, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and NivolumabMoshe C Ornstein, Laeth George, Wei Wei, et al.
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Advances in Hematology & Oncology : H&O|April 11, 2023
Management of testicular germ cell tumorsChristopher E Wee, Timothy D Gilligan
Southern Medical Journal|February 5, 2020
Changes in Health and Well-Being during Residents' TrainingChristopher E Wee, Jacob Petrosky, Lauren Mientkiewicz, et al.
The Prostate|July 13, 2021
Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experienceChristopher E Wee, Brian A Costello, Jacob J Orme, et al.
Frontiers in Endocrinology|July 17, 2023
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionJarrell Imamura, Shinjini Ganguly, Andrew Muskara, et al.
Journal of Oncology Practice|June 22, 2017
Analysis of Origins of Admission for Solid Tumor Oncology Inpatients: Disease Severity and OutcomesChristopher E Wee, Lindsey M Goodman, Leticia Varella, et al.
Clinical Genitourinary Cancer|January 20, 2024
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse EventsAmanda Nizam, Ryan K Rader, Alice Tzeng, et al.
Clinical Genitourinary Cancer|November 6, 2023
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell CarcinomaJames Schuster, Iris Y Sheng, Chandana A Reddy, et al.
Clinical Genitourinary Cancer|August 29, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and NivolumabMoshe C Ornstein, Laeth George, Wei Wei, et al.
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
Pageof 1